Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594723 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
A Phase 2 study of Neoplasms, Hematologic, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT01594723: Active Phase 2 study of Neoplasms, Hematologic, sponsored by Eli Lilly and Company.
NCT01594723 is a Phase 2 study of Neoplasms, Hematologic that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01594723, a Phase 2 study of Neoplasms, Hematologic, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.
Conditions Studied
Interventions
- DRUG 120 mg LY2784544
Study Locations (20)
Tennessee
- Baptist Cancer Center - Memphis
- Sarah Cannon Cancer Center - Nashville
- Tennessee Oncology PLLC - Nashville
Florida
- Lakeland Regional Cancer Center - Lakeland
- Palm Beach Cancer Institue - West Palm Beach
New York
- Weill Cornell Medical College - New York
- Albert Einstein College of Medicine - The Bronx
Ohio
- Cleveland Clinic Foundation - Cleveland
- Mid Ohio Oncology Hematology - Columbus
Arkansas
- Highlands Oncology Group - Duplicate 2 - Rogers
California
- Providence St. Joseph's Medical Center - Burbank
Connecticut
- Norwalk Hospital - Norwalk
Illinois
- Ingalls Memorial Hospital - Harvey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-05-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT01594723 still lists
NCT01594723 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Neoplasms, Hematologic appearing as the primary indexed condition, and to 1 intervention - of which 120 mg LY2784544 is the first listed.
NCT01594723 names 20 study sites across 15 states, led by Tennessee, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01594723 about?
NCT01594723 is a clinical study titled "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms". The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure ...
What is the current status of trial NCT01594723?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2012-05-22. Estimated completion is 2026-12.
What conditions does trial NCT01594723 study?
This clinical trial studies the following conditions: Neoplasms, Hematologic.
What interventions are being tested in trial NCT01594723?
The interventions under investigation include: 120 mg LY2784544 (DRUG).
Who is sponsoring clinical trial NCT01594723?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01594723 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Hematologic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01594723's enrollment target sits among peer trials
110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI